Our faculty secure major research grants from various National Institutes of Health as well as private sources.
Jonathan Bard, PhD
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers. Jonathan Bard (Co-Investigator). NCI. $3,823,553. 8/1/2023-7/1/2028.
Cell Type Specific Activation of Endoplasmic Reticulum Sensor, ATF6, Drives Fibrotic Remodeling in Pericytes and SMC. Jonathan Bard (Co-Investigator). American Heart Association. $300,000. 7/1/2025-6/1/2028.
Impact of Sex on Mitochondrial and Epigenetic Mechanisms in Age-Related Macular Degeneration. Jonathan Bard (Co-Investigator). National Institutes of Health. $2,231,306. 4/1/2025-3/1/2029.
Regulatory Mechanisms in Salivary Gland Development and Regeneration. Jonathan Bard (Co-Investigator). NIDCR. $3,743,537. 7/1/2024-6/1/2029.
National HTX Center: Enabling Access to State-of-the-Art Crystallization Capabilities. Sarah Bowman (Principal Investigator). National Institutes of Health. $4,910,000. 7/1/2021-6/1/2026.
New techniques for detecting and handling nanocrystals for cutting edge structural biology methods. Sarah Bowman (Principal Investigator). NIH. $1,570,000. 9/1/2022-8/1/2026.
Acquisition of an SPT Labtech Mosquito Administrative Supplement. Sarah Bowman (Principal Investigator). NIH. $167,746. 8/1/2025-9/1/2026.
Probing evolutionary pathways in metalloprotein structure and function from emerging bacterial pathogens. Sarah Bowman (Principal Investigator). University at Buffalo Bridge Funding Opportunity-UB LAUNCH & Department of Biochemistry. $50,000. 11/1/2025-8/1/2026.
Studying structure and function of bacterial proteins using structural biology and enzymatic assays. Sarah Bowman (Principal Investigator). University at Buffalo Undergraduate Research and Creative Activities Program. $15,500. 1/1/2026-12/1/2026.
Genomic and epigenomic investigations of the transcriptional regulatory network of skin keratinocytes in defined genetic models. Michael Buck (Co-Investigator). NIH. $1,754,500. 3/1/2018-1/1/2024.
Protective effects of dietary pulse flours on the transgenerational influence of maternal obesity. Michael Buck (Co-Investigator). United States Department of Agriculture. $480,255. 9/1/2020-2/1/2024.
Therapeutic targeting of master regulators in non-canonical AR driven advanced lethal prostate cancers. Michael Buck (Co-Investigator). NCI. $3,823,553. 8/1/2023-7/1/2028.
Examining neurological disability in Mowat-Wilson syndrome using brain organoids. Rebekah Charney (Principal Investigator). The Mowat-Wilson Syndrome Foundation. 7/1/2022-6/1/2025.
The role of the transcriptional repressor ZEB2 in human neural crest cell formation and craniofacial pathology. Rebekah Charney (Principal Investigator). NIH-NIDCR R00. 9/1/2024-8/1/2027.
Structural regulation in mitochondrial vitamin-D and vitamin-A metabolizing cytochromes P450. D. Fernando Estrada (Principal Investigator). National Institute of General Medical Sciences. $1,987,200. 9/1/2019-8/1/2024.
Impact of Pseudomonas aeruginosa cytochrome P450 enzymes and secondary metabolites on drug metabolism and disposition in the cystic fibrosis patient. D. Fernando Estrada (Co-Principal Investigator). NIAID. $632,183. 1/1/2024-1/1/2028.
Noncompetitive inhibition of CYP121 dimers of Mycobacterium tuberculosis. D. Fernando Estrada (Principal Investigator). NIAID. $442,750. 7/1/2024-7/1/2026.
Mechanisms of Gene Regulatory Network Evolution. Marc Halfon (Principal Investigator). NSF. $1,106,456. 9/1/2019-8/1/2024.
Regulatory Element Discovery in Sequenced Insect Species. Marc Halfon (Principal Investigator). USDA. $445,911. 6/1/2019-5/1/2023.
REDfly: The regulatory element database for Drosophila and other insects. Marc Halfon (Principal Investigator). NIH/NIGMS. $1,415,154. 9/1/2021-8/1/2025.
Measuring functional similarity between transcriptional enhancers using deep learning. Marc Halfon (Co-Investigator). NIH/NHGRI. $118,818. 9/1/2021-8/1/2024.
Ferroportin and APP: Regulation of Iron Trafficking at the Blood-Brain Barrier. Daniel Kosman (Principal Investigator). NIDDS. $1,955,930. 8/1/2017-5/1/2024.
Molecular mechanisms of small molecule iron chelating antioxidants. Daniel Kosman (Principal Investigator). Alterity Therapeutics Annual MRSA 2020-2023 Dollar amount below for 2023. $253,573. 1/1/2020-7/1/2025.
Poly(I:C) Drug Repurposing and SFRP-2 Gene Therapy in Tooth Regeneration. Techung Lee (Co-Principal Investigator). Robert Wood Johnson Foundation. $470,400. 2/1/2024-1/1/2028.
The Metagenomics Education Partnership. Norma Nowak (Co-Investigator). NIH/NIGMS. $1,288,542. 6/1/2020-4/1/2026.
Genomic surveillance of SARS-CoV-2 in Western New York. Norma Nowak (Co-Investigator). NYSDOH. $2,000,000. 10/1/2021-6/1/2025.
Personalizing Head and Neck Squamous Cell Carcinoma (HNSCC). Norma Nowak (Principal Investigator). Community Foundation of Greater Buffalo. $22,380. 12/1/2023-12/1/2024.
Modulation of oligodendrocyte development by voltage-operated calcium channels. Yungki Park (Co-Investigator). NIH. $1,993,750. 12/1/2021-11/1/2026.
Elucidating the role of Nucks1 in Myrf expression and central nervous system myelination. Yungki Park (Principal Investigator). UB Neuroscience. $40,000. 10/1/2024-12/1/2025.
Systematic discovery of Olig2 upstream regulators for central nervous system myelination. Yungki Park (Principal Investigator). NIH. $440,275. 7/1/2025-6/1/2027.
Genomic and functional investigations of the transcriptional regulatory network of tooth enamel development. Yungki Park (Co-Investigator). NIH. $1,956,180. 7/1/2023-6/1/2028.
Protective effects of dietary pulse flours on the transgenerational influence of maternal obesity. Mulchand Patel (Co-Investigator). USDA-National Institute of Food and Agriculture. $480,255. 9/1/2020-9/1/2023.
Alpha Lipoic acid as maternal supplement in obese pregnancies. Mulchand Patel (Co-Principal Investigator). NIH, National Center for Complementary and Integrative Health. $438,625. 2/1/2022-1/1/2024.
Protective mechanisms of pulse crop consumption in the development of non-alcoholic fatty liver disease in mothers and offspring across life stages. Mulchand Patel (Co-Principal Investigator). USDA, USDA Pulse Crop Health Initiative. $421,744. 8/1/2023-7/1/2026.
CTSA UM1 State University of New York at Buffalo. Gabriela Popescu (Co-Investigator). National Center for Advancing Translational Sciences. $3,710,000. 1/1/2025-1/1/2031.
Genomic and epigenomic investigations of the transcriptional regulatory network of skin keratinocytes in defined genetic models. Satrajit Sinha (Principal Investigator). NIAMS. 3/1/2018-12/1/2023.
Genomic and functional investigations of the transcriptional regulatory network of salivary gland morphogenesis and stem cell fate choices in defined genetic models. Satrajit Sinha (Co-Principal Investigator). NIDCR. 3/1/2018-2/1/2024.
High resolution genomic and epigenomic mapping of the human salivary gland. Satrajit Sinha (Principal Investigator). NIH. $440,922. 8/1/2023-7/1/2025.
Genomic and functional investigations of the transcriptional regulatory network of tooth enamel development. Satrajit Sinha (Co-Investigator). NIH. $627,934. 7/1/2023-6/1/2028.
Genomic surveillance of SARS-CoV-2 in Western New York. Jennifer Surtees (Principal Investigator). New York State Department of Health `. $5,700,000. 9/1/2021-7/1/2026.
Integrated Ecosystems for Pandemic Prevention. Jennifer Surtees (Principal Investigator). NSF. $1,000,000. 9/1/2022-2/1/2026.
Role of Msh2-Msh3 in determining outcomes in pathways of DNA metabolism. Jennifer Surtees (Principal Investigator). National Science Foundation. $400,000. 9/1/2023-8/1/2027.
Characterizing the role of Elevated dNTP pools in sensitizing the replisome. Jennifer Surtees (Principal Investigator). NIGMS. $2,448,745. 9/1/2024-6/1/2029.
Coordination of High Fidelity Replication with Mutagenic Translesion Synthesis. Mark Sutton (Principal Investigator). NIH/GMS. $1,414,219. 2/1/2019-11/1/2024.
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa. Mark Sutton (Co-Principal Investigator). NIH, NIAID. $3,850,992. 5/1/2022-4/1/2027.
Regulation of the Kidney Cancer Epigenome by Oncometabolite L-2-Hydroxyglutarate. Mary Taub (Co-Principal Investigator). NCI. $372,110. 7/1/2016-7/1/2023.
Gulla S, Sharma T, Gardner E, Li C, Purohit TA, Xue C, Colligan S, Shyam Sundar S, Yang B, Trostel SY, Capaldo B, Bard JE, Ogunbowale T, Jawadwala A, Ma M, Qu J, Karzai F, Pili R, Jarrard DF, Sowalsky AG, VanderWeele DJ, Adelaiye-Ogala R. (2026) MECOM Function is Critical for AR-Driven Treatment-Resistant Prostate Cancer. Cancer research (Jan).